Suppr超能文献

利福平对人肝细胞中药物转运体基因表达的调控及微小RNA的关联

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

作者信息

Benson Eric A, Eadon Michael T, Desta Zeruesenay, Liu Yunlong, Lin Hai, Burgess Kimberly S, Segar Matthew W, Gaedigk Andrea, Skaar Todd C

机构信息

Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine Indianapolis, IN, USA.

Department of Medical and Molecular Genetics, Indiana University School of Medicine Indianapolis, IN, USA.

出版信息

Front Pharmacol. 2016 Apr 26;7:111. doi: 10.3389/fphar.2016.00111. eCollection 2016.

Abstract

UNLABELLED

Membrane drug transporters contribute to the disposition of many drugs. In human liver, drug transport is controlled by two main superfamilies of transporters, the solute carrier transporters (SLC) and the ATP Binding Cassette transporters (ABC). Altered expression of these transporters due to drug-drug interactions can contribute to differences in drug exposure and possibly effect. In this study, we determined the effect of rifampin on gene expression of hundreds of membrane transporters along with all clinically relevant drug transporters.

METHODS

In this study, primary human hepatocytes (n = 7 donors) were cultured and treated for 24 h with rifampin and vehicle control. RNA was isolated from the hepatocytes, mRNA expression was measured by RNA-seq, and miRNA expression was analyzed by Taqman OpenArray. The effect of rifampin on the expression of selected transporters was also tested in kidney cell lines. The impact of rifampin on the expression of 410 transporter genes from 19 different transporter gene families was compared with vehicle control.

RESULTS

Expression patterns of 12 clinically relevant drug transporter genes were changed by rifampin (FDR < 0.05). For example, the expressions of ABCC2, ABCB1, and ABCC3 were increased 1.9-, 1.7-, and 1.2-fold, respectively. The effects of rifampin on four uptake drug transporters (SLCO1B3, SLC47A1, SLC29A1, SLC22A9) were negatively correlated with the rifampin effects on specific microRNA expression (SLCO1B3/miR-92a, SLC47A1/miR-95, SLC29A1/miR-30d#, and SLC22A9/miR-20; r < -0.79; p < 0.05). Seven hepatic drug transporter genes (SLC22A1, SLC22A5, SLC15A1, SLC29A1, SLCO4C1, ABCC2, and ABCC4), whose expression was altered by rifampin in hepatocytes, were also present in a renal proximal tubular cell line, but in renal cells rifampin did not alter their gene expression. PXR expression was very low in the kidney cells; this may explain why rifampin induces gene expression in a tissue-specific manner.

CONCLUSION

Rifampin alters the expression of many of the clinically relevant hepatic drug transporters, which may provide a rational basis for understanding rifampin-induced drug-drug interactions reported in vivo. The relevance of its effect on many other transporters remains to be studied.

摘要

未标记

膜药物转运体参与多种药物的处置。在人肝脏中,药物转运由两个主要的转运体超家族控制,即溶质载体转运体(SLC)和ATP结合盒转运体(ABC)。药物 - 药物相互作用导致这些转运体的表达改变,可能会导致药物暴露差异以及可能的效应差异。在本研究中,我们确定了利福平对数百种膜转运体以及所有临床相关药物转运体基因表达的影响。

方法

在本研究中,培养原代人肝细胞(n = 7名供体),并用利福平和溶剂对照处理24小时。从肝细胞中分离RNA,通过RNA测序测量mRNA表达,并通过Taqman OpenArray分析miRNA表达。还在肾细胞系中测试了利福平对选定转运体表达的影响。将利福平对19个不同转运体基因家族的410个转运体基因表达的影响与溶剂对照进行比较。

结果

利福平改变了12个临床相关药物转运体基因的表达模式(FDR < 0.05)。例如,ABCC2、ABCB1和ABCC3的表达分别增加了1.9倍、1.7倍和1.2倍。利福平对四种摄取药物转运体(SLCO1B3、SLC47A1、SLC29A1、SLC22A9)的影响与利福平对特定微小RNA表达的影响呈负相关(SLCO1B3/miR - 92a、SLC47A1/miR - 95、SLC29A1/miR - 30d#和SLC22A9/miR - 20;r < -0.79;p < 0.05)。肝细胞中利福平改变其表达的七个肝脏药物转运体基因(SLC22A1、SLC22A5、SLC15A1、SLC29A1、SLCO4C1、ABCC2和ABCC4)也存在于肾近端小管细胞系中,但在肾细胞中利福平未改变它们的基因表达。肾细胞中PXR表达非常低;这可能解释了为什么利福平以组织特异性方式诱导基因表达。

结论

利福平改变了许多临床相关肝脏药物转运体的表达,这可能为理解体内报道的利福平诱导的药物 - 药物相互作用提供合理依据。其对许多其他转运体的影响的相关性仍有待研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c2d/4845040/4b10fbe2a89f/fphar-07-00111-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验